Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.39 |
| ▸ | ADH1C | P00326 | 2/20 | 0.39 |
| ▸ | ADH1A | P07327 | 2/20 | 0.39 |
| ▸ | ADH7 | P40394 | 2/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401029 | 0.84 | ADH1B (0.37) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL7282330 | 0.81 | ADH1B (0.43) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL1401058 | 0.79 | ADH1B (0.33) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL5651631 | 0.79 | CYP1A2 (0.52) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL23876838 | 0.78 | DGKA (0.43) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL9099964 | 0.78 | DGKA (0.56) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL1401272 | 0.77 | DGKA (0.40) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL7367625 | 0.76 | ADH1B (0.39) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL24013228 | 0.76 | ADH1B (0.36) | ADH1BADH1CADH1AADH7DGKA | |
| SCHEMBL8176277 | 0.75 | CYP1A2 (0.52) | ADH1BADH1CADH1AADH7DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | Yamaguchi, Koushi (JP) | 2023-04-06 | — | — | US | disclosed |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | Yamaguchi, Kouchi (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3977995-A1 | TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS | Yamaguchi, Koushi (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3900729-A1 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | Yamaguchi, Koushi (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3246036-B1 | MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME | YAMAGUCHI KOUSHI (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113226331-A | Medicine for improving infertility or pregnancy state | 山口晃史 | 2021-08-06 | — | — | CN | disclosed |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | YAMAGUCHI KOUSHI (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3834826-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP | Yamaguchi, Koushi (JP) | 2021-06-16 | — | — | EP | disclosed |
| CN-112533599-A | Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship | 山口晃史 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020129348-A1 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | 山口 晃史 | 2020-06-25 | — | — | WO | disclosed |
| US-5110811-A | Antibody inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0474126-A1 | Ointments containing tricyclic compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-11 | — | — | EP | disclosed |
| WO-1992000313-A1 | TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991019495-A1 | USE OF A MACROLIDE COMPOUND SUCH AS FK 506 FOR MANUFACTURING A MEDICAMENT FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA AND BASEDOW'S DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991017754-A1 | METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-28 | — | — | WO | disclosed |
| EP-0444659-A2 | A pharmaceutical solution comprising derivatives of FK506 | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-04 | — | — | EP | disclosed |
| EP-0428169-A2 | Aqueous liquid formulations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
| EP-0423714-A2 | Hair revitalizing agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0406791-A2 | Aqueous liquid composition for external use | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4929611-A | ANTIBODY INHIBITORS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | PGF, SLC10A1, SLC26A4 | ADH1B 146/4885ADH1C 354/4885ADH1A 267/4885 |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | PGF, SLC10A1, SLC26A4 | ADH1B 105/4885ADH1C 315/4885ADH1A 214/4885 |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | PGF, HAMP, HLA-DRB1 | ADH1B 2140/4885ADH1C 2396/4885ADH1A 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.